Needham & Company LLC reaffirmed their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $8.00 price objective on the stock. Separately, Oppenheimer reissued an outperform rating and issued a $9.00 price target on shares of Trevi Therapeutics in a […]